Quo Vadis with Bacterial Resistance? J. D. Williams State-Of-The-Art Presentations 28 November 2012 Pages: 1 - 9
Quinolone Mode of Action David C. Hooper State-Of-The-Art Presentations 28 November 2012 Pages: 10 - 15
Classification and Structure-Activity Relationships of Fluoroquinolones André BryskierJean-François Chantot State-Of-The-Art Presentations 28 November 2012 Pages: 16 - 28
Mechanisms of Resistance to Fluoroquinolones: State-of-the-Art 1992–1994 Laura J. V. Piddock State-Of-The-Art Presentations 28 November 2012 Pages: 29 - 35
Epidemiology of Quinolone Resistance: Europe and North and South America Fred W. GoldsteinJ. F. Acar State-Of-The-Art Presentations 28 November 2012 Pages: 36 - 42
Epidemiology of Quinolone Resistance John Turnidge State-Of-The-Art Presentations 28 November 2012 Pages: 43 - 47
In Vitro Activity of Fluoroquinolones against Gram-Positive Bacteria George M. Eliopoulos State-Of-The-Art Presentations 28 November 2012 Pages: 48 - 57
Activity of Quinolones against Gram-Positive Cocci: Clinical Features Helen Giamarellou State-Of-The-Art Presentations 28 November 2012 Pages: 58 - 66
Activity of Quinolones against Mycobacteria Michael R. Jacobs State-Of-The-Art Presentations 28 November 2012 Pages: 67 - 75
Quinolone Activity against Anaerobes: Microbiological Aspects Peter C. Appelbaum State-Of-The-Art Presentations 28 November 2012 Pages: 76 - 80
Effect of Quinolones on the Human Intestinal Microflora Carl Erik Nord State-Of-The-Art Presentations 28 November 2012 Pages: 81 - 85
Prophylactic Use of the New Quinolones for Prevention of Nosocomial Infection in the Intensive Care Unit Peter D. PotgieterJanet M. J. Hammond State-Of-The-Art Presentations 28 November 2012 Pages: 86 - 91
Fluoroquinolones in Paediatrics — 1995 Ron Dagan State-Of-The-Art Presentations 28 November 2012 Pages: 92 - 99
Quinolones and Osteomyelitis: State-of-the-Art Daniel P. LewFrancis A. Waldvogel State-Of-The-Art Presentations 28 November 2012 Pages: 100 - 111
Quinolones in the Elderly Tom Bergan State-Of-The-Art Presentations 28 November 2012 Pages: 112 - 114
Quinolones in Sexually Transmitted Diseases Geoffrey L. Ridgway State-Of-The-Art Presentations 28 November 2012 Pages: 115 - 122
The Use of Fluoroquinolones in Sexually Transmitted Diseases in Southeast Asia Apichati Sivayathorn State-Of-The-Art Presentations 28 November 2012 Pages: 123 - 127
Role of Quinolones in the Treatment of Diarrhoeal Diseases H. Erdal Akalin State-Of-The-Art Presentations 28 November 2012 Pages: 128 - 131
The New Quinolones in the Treatment of Diarrhoea and Typhoid Fever Anis Waiz State-Of-The-Art Presentations 28 November 2012 Pages: 132 - 135
Short Course Quinolone Therapy of Typhoid Fever in Developing Countries Benjamin M. Limson State-Of-The-Art Presentations 28 November 2012 Pages: 136 - 138
The Use of Quinolones as Therapy in Granulocytopenic Cancer Patients V. Krcméry Jr State-Of-The-Art Presentations 28 November 2012 Pages: 139 - 143
The Role of New Quinolones in the Treatment of Respiratory Tract Infections Roger G. Finch State-Of-The-Art Presentations 28 November 2012 Pages: 144 - 151
Veterinary Use of New Quinolones in Japan Shinichi Nakamura State-Of-The-Art Presentations 28 November 2012 Pages: 152 - 158
Fluoroquinolone Toxicities Paul S. Lietman State-Of-The-Art Presentations 28 November 2012 Pages: 159 - 163
Direct Analysis of Resistance in the Cutaneous Microflora during Treatment of Acne Vulgaris with Topical 1% Nadifloxacin and 2% Erythromycin R. A. BojarN. HittelK. T. Holland Oraland Poster Presentations 28 November 2012 Pages: 164 - 167
Quinolone Susceptibility of Multiply-Resistant Flavobacterium meningosepticum Clinical Isolates in One Urban Hospital Nancy K. BolashHans H. Liu Oraland Poster Presentations 28 November 2012 Pages: 168 - 170
The Susceptibility of Mycobacterium tuberculosis and Atypical Mycobacteria in Northern Israel Z. CahanaR. GabbayR. Raz Oraland Poster Presentations 28 November 2012 Pages: 171 - 172
Changes in Susceptibility to Ciprofloxacin in a Community in Northern Israel Z. CahanaA. GilboaR. Raz Oraland Poster Presentations 28 November 2012 Pages: 173 - 174
Ciprofloxacin Resistance in Clinical Isolates of Pseudomonas aeruginosa from Italian Patients Giampaolo CortiF. ParadisiP. Nicoletti Oraland Poster Presentations 28 November 2012 Pages: 175 - 176
Susceptibility to New Quinolones of Pseudomonas aeruginosa Isolated from a Patient with Chronic Respiratory Tract Infection H. GotoF. AdachiK. Yuasa Oraland Poster Presentations 28 November 2012 Pages: 177 - 178
Resistance among Important Pathogens and the Antimicrobial Activity of Parenteral Fluoroquinolones at 43 US Medical Centres Ronald N. JonesEric N. KehrbergMeredith E. Erwin Oraland Poster Presentations 28 November 2012 Pages: 179 - 181
Analysis of Quinolone Resistance Genes in a Clinical Isolate of Quinolone-Resistant MRSA Tsuyoshi KojimaJ. YamagishiS. Nakamura Oraland Poster Presentations 28 November 2012 Pages: 182 - 184
Effect of Quinolone Use on Antimicrobial Susceptibility Patterns over a 5-Year Period John SegretiRita Connelly Oraland Poster Presentations 28 November 2012 Pages: 185 - 187
Fluoroquinolone Resistance Patterns after Formulary Addition of Ofloxacin Gary E. Stein Oraland Poster Presentations 28 November 2012 Pages: 188 - 189
Quinolone Resistance Mechanisms in Klebsiella pneumoniae Yong-hong XiaoAkihiro KitamuraKenichi Sato Oraland Poster Presentations 28 November 2012 Pages: 190 - 191
Uptake of Ciprofloxacin in Methicillin-Resistant Staphylococcus aureus Yong-xin ZhangYu-qing WangDe-mei Zhu Oraland Poster Presentations 28 November 2012 Pages: 192 - 193
Activities of Ciprofloxacin and Sparfloxacin against Streptococcus pneumoniae A. Dalhoff Oraland Poster Presentations 28 November 2012 Pages: 194 - 196
Pharmacodynamics of Quinolones A. Dalhoff Oraland Poster Presentations 28 November 2012 Pages: 197 - 199
In Vitro Susceptibility to Ciprofloxacin of Bacterial Strains Isolated from Chronic Otitis Media and Chronic Sinusitis O. GaillotP. Berche Oraland Poster Presentations 28 November 2012 Pages: 200 - 202
Comparative In Vitro Activity of Ciprofloxacin vs 8 Antimicrobial Agents against Nosocomial Multiresistant P. aeruginosa Strains E. J. Giamarellos-BourboulisP. GreckaHelen Giamarellou Oraland Poster Presentations 28 November 2012 Pages: 203 - 204
In Vitro Antimicrobial Activity of CP-99,219, a New 7-Azabicyclonaphthyridone Ronald N. Jones Oraland Poster Presentations 28 November 2012 Pages: 205 - 207
Evaluation of the Anti-Rickettsial Activity of Fluoroquinolones Gershon KerenAvi ItzhakiAvi Keysary Oraland Poster Presentations 28 November 2012 Pages: 208 - 210
Activity of Levofloxacin, Ofloxacin, D-Ofloxacin and Ciprofloxacin against Systemic and Respiratory Tract Infections in Laboratory Animals N. KieselK. -H. GewenigerA. Bryskier Oraland Poster Presentations 28 November 2012 Pages: 211 - 214
Susceptibility of Bacterial Isolates from Complicated Skin and Skin Structure Infections to Cefazolin, Imipenem-Cilastatin, Ciprofloxacin and Ofloxacin Hans H. LiuNancy K. BolashRandall A. Lynch Oraland Poster Presentations 28 November 2012 Pages: 215 - 218
In Vitro and In Vivo Antibacterial Activities of Broad Spectrum Quinolones against Clinical Bacterial Isolates T. MatsumotoK. TatedaK. Yamaguchi Oraland Poster Presentations 28 November 2012 Pages: 219 - 221
Comparative In Vitro Activity of BAY Y 3118 with Other Fluoroquinolones G. MolinariGian Carlo Schito Oraland Poster Presentations 28 November 2012 Pages: 222 - 225
Activity of New 4-Quinolones in Combination with Erythromycin or Tetracycline against S. pneumoniae I. MorrisseyJ. T. Smith Oraland Poster Presentations 28 November 2012 Pages: 226 - 227
The New 4-Quinolones DU-6859a and DV-7751a Show Enhanced Activity against Streptococcus pneumoniae I. MorrisseyJ. T. Smith Oraland Poster Presentations 28 November 2012 Pages: 228 - 229
In Vitro Activity of Nadifloxacin against both Methicillin-Susceptible and -Resistant Clinical Isolates of Staphylococcus aureus from Patients with Skin Infections S. NishijimaS. NamuraM. Fujita Oraland Poster Presentations 28 November 2012 Pages: 230 - 232
In Vitro Activity of New Quinolones against Anaerobic Bacteria Carl Erik NordAnn LindmarkIngela Persson In Vitro and In Vivo Antibacterial Activity 28 November 2012 Pages: 233 - 234
